Journal of Clinical Epidemiology
Volume 63, Issue 4 , Pages 422-427 , April 2010

Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length

  • Helga Gardarsdottir

      Affiliations

    • Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands
    • ,
  • Patrick C. Souverein

      Affiliations

    • Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands
    • ,
  • Toine C.G. Egberts

      Affiliations

    • Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands
    • Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, the Netherlands
    • ,
  • Eibert R. Heerdink

      Affiliations

    • Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands
    • Corresponding Author InformationCorresponding author. Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Sorbonnelaan 16, 3584 CA Utrecht, the Netherlands. Tel.: +31-30-2537324; fax: +31-30-2539166.

,Accepted 3 July 2009.

References 

  1. Meijer WE, Heerdink ER, Leufkens HG, Herings RM, Egberts AC, Nolen WA. Incidence and determinants of long-term use of antidepressants. Eur J Clin Pharmacol. 2004;60:57–61
  2. Mantel-Teeuwisse AK, Klungel OH, Verschuren WM, Porsius A, de Boer A. Comparison of different methods to estimate prevalence of drug use by using pharmacy records. J Clin Epidemiol. 2001;54:1181–1186
  3. Knoester PD, Belitser SV, Deckers CL, Keyser A, Renier WO, Egberts AC, et al. Patterns of lamotrigine use in daily clinical practice during the first 5 years after introduction in the Netherlands. J Clin Pharm Ther. 2004;29:131–138
  4. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen. J Hypertens. 2004;22:1831–1837
  5. D'Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm. 2008;14:291–301
  6. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, de Boer A, Herings RM. Long term persistence with statin treatment in daily medical practice. Heart. 2004;90:1065–1066
  7. Tsiropoulos I, Andersen M, Nymark T, Lauritsen J, Gaist D, Hallas J. Exposure to antiepileptic drugs and the risk of hip fracture: a case-control study. Epilepsia. 2008;40:2092–2099
  8. Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sorensen HT. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology. 2007;133:755–760
  9. Katon W, Cantrell CR, Sokol MC, Chiao E, Gdovin JM. Impact of antidepressant drug adherence on comorbid medication use and resource utilization. Arch Intern Med. 2005;165:2497–2503
  10. Keene MS, Eaddy MT, Nelson WW, Sarnes MW. Adherence to paroxetine CR compared with paroxetine IR in a Medicare-eligible population with anxiety disorders. Am J Manag Care. 2005;11(12 Suppl):S362–S369
  11. Dunn RL, Donoghue JM, Ozminkowski RJ, Stephenson D, Hylan TR. Longitudinal patterns of antidepressant prescribing in primary care in the UK: comparison with treatment guidelines. J Psychopharmacol. 1999;13(2):136–143
  12. Vanelli M, Coca-Perraillon M. Role of patient experience in antidepressant adherence: a retrospective data analysis. Clin Ther. 2008;30:1737–1745
  13. Sheehan DV, Keene MS, Eaddy M, Krulewicz S, Kraus JE, Carpenter DJ. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs. 2008;22:963–973
  14. Rasmussen JN, Gislason GH, Rasmussen S, Abildstrom SZ, Schramm TK, Køber L, et al. Use of statins and beta-blockers after acute myocardial infarction according to income and education. J Epidemiol Community Health. 2007;61:1091–1097
  15. Kerr EA, McGlynn EA, Van Vorst KA, Wickstrom SL. Measuring antidepressant prescribing practice in a health care system using administrative data: implications for quality measurement and improvement. Jt Comm J Qual Improv. 2000;26:203–216
  16. Herings RM, Bakker A, Stricker BH, Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health. 1992;46:136–140
  17. Buurma H, Bouvy ML, De Smet PA, Floor-Schreudering A, Leufkens HG, Egberts AC. Prevalence and determinants of pharmacy shopping behaviour. J Clin Pharm Ther. 2008;33:17–23
  18. Anonymous . Anatomical Therapeutic Chemical (ATC) classification index. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2002;
  19. Prien RF, Kupfer DJ. Continuation drug therapy for major depressive episodes: how long should it be maintained?. Am J Psychiatry. 1986;143:18–23
  20. Kupfer DJ. Lessons to be learned from long-term treatment of affective disorders: potential utility in panic disorder. J Clin Psychiatry. 1991;52(Suppl):12–16discussion 17
  21. Gardarsdottir H, Heerdink ER, van Dijk L, Egberts AC. Indications for antidepressant drug prescribing in general practice in the Netherlands. J Affect Disord. 2007;98(1–2):109–115

PII: S0895-4356(09)00204-2

doi: 10.1016/j.jclinepi.2009.07.001

Journal of Clinical Epidemiology
Volume 63, Issue 4 , Pages 422-427 , April 2010

Article Tools

* Image Usage & Resolution